INBX · Inhibrx Biosciences, Inc.
$87.16
+3.27 (+3.89%)
At close · Aug 6
Market Cap
$1.23B
Shares
14.67M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$83.89
Open$84.05
Day$82.58–85.75
52W$20.55–155.29
Avg vol 30d292K
Short int3.4M · 23.4% float · 9.0d
Short vol86%
Last earningsMay 11, 2026
DataMay 2024–Aug 2026
Filing10-Q · May 14
Up next
Next earnings call
Aug 8, 2026
Est · unconfirmed
· this week
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.46
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
−9%
below
RSI (14)
43
neutral
MACD trend
Positive
52-week position
47%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
+2%
trailing
YTD return
+6%
this year
Relative strength
−9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $92 › 200d $85 — 50d above 200d
Institutional flow
Accumulating
34 of 137 funds reported for Jun 30 · net +63.7K sh shares · +9 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
23.41% of float · ▼ -0.4% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
137 holders — mid 2-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
+550%
Y/Y
EPS growth
−108%
Y/Y
Free cash flow
$-129.8M
Balance sheet
$23.7M
net cash
Quant / Vol
risk profile
Volatility
129%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
−9%
Bearish
RSI (14)
43
Neutral
MACD trend
Positive
Bullish
52-week position
47%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $92 › 200d $85 — 50d above 200d
Institutional flow
Accumulating
34 of 137 funds reported for Jun 30 · net +63.7K sh shares · +9 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
23.41% of float · ▼ -0.4% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
137 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $21
Now $84 · 47%
52-wk high $155
vs 200-day avg -1%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INBX
this stock
Inhibrx Biosciences, Inc.
|
$1.23B | +6.2% | -88.9% | — | 23.4% |
|
ONC
BeOne Medicines Ltd.
|
$484.13B | +7.8% | +22179.2% | 744.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.89B | +6.9% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.13B | -0.2% | +20.8% | 19.0 | 3.4% |
|
ARGX
Argenx SE
|
$54.30B | +3.2% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INBX | +5.9% | -13.6% | +2.3% | +2.2% | +6.2% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | +0.3% | -16.9% | -8.9% | -0.8% | -6.7% |